ISCO Chairman Kenneth Aldrich to
Discuss “State of the Company”
International Stem Cell Corporation (OTCBB:ISCO),
a California-based biotechnology company creating human stem cell lines
from unfertilized eggs, today announced that it is has scheduled a
conference call for February 5, 2010 at 10:00 a.m. PST. ISCO Chairman
Mr. Kenneth Aldrich will discuss both the present status of the company
and its vision for the coming year. The dial-in number for participants
is 1 (800) 774-6070 and the pass code ID is 8273 225#. An alternate
dial-in number is 1 (630) 691-2753 and the pass code will be the same
for both numbers. A replay of the call will be available via the
Investor Relations link on the company's web site at: http://www.internationalstemcell.com.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in the creation of
parthenogenetic human stem cells from unfertilized eggs (oocytes). Like
embryonic stem cells (ESCs), hpSCs are pluripotent (i.e. have the
capacity to become almost any cell type in the body), yet avoid ethical
issues associated with use or destruction of viable human embryos. ISCO
scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal
immune rejection after transplantation into hundreds of millions of
individuals of differing sexes, ages and racial groups. This offers the
potential to create the first true stem cell bank, UniStemCell™, while
avoiding the ethical issue of using fertilized eggs. ISCO also produces
and markets specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology. More
information is available at ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com Or International
Stem Cell Corporation Jeffrey Janus, Sr. VP, Operations President
& CEO, Lifeline Cell Technology 760-940-6383 jjanus@intlstemcell.com
|